MIRA Pharmaceuticals financials
$0.8715−3.52%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.2M | -$1.1M | -$5.8M | -$1.3M | -$1.5M | -$1.8M | -$2.4M | -$2.1M | -$1.7M | -$1.8M | -$3.1M | -$3.2M |
| Net income | -$1.2M | -$1.2M | -$6.0M | -$22.7M | -$1.5M | -$1.8M | -$2.4M | -$2.0M | -$1.7M | -$1.7M | -$5.8M | -$3.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.03 | $-0.03 | $-0.14 | $-1.18 | $-0.09 | $-0.11 | $-0.14 | $-0.14 | $-0.11 | $-0.15 | $-0.53 | $-0.26 |
| EBITDA | -$1.2M | -$1.1M | -$5.8M | -$1.3M | -$1.5M | -$1.8M | -$2.4M | -$2.1M | -$1.7M | -$1.8M | -$3.1M | -$3.2M |
| Operating cash flow | -$1.2M | -$1.2M | -$1.1M | -$1.1M | -$799.7K | -$1.6M | -$1.8M | -$1.8M | -$863.9K | -$1.0M | -$1.0M | -$1.8M |
| Free cash flow | -$1.2M | -$1.2M | -$1.1M | -$1.1M | -$799.7K | -$1.6M | -$1.8M | -$1.8M | -$863.9K | -$1.0M | -$1.0M | -$1.8M |
| Diluted shares | 42.0M | 41.9M | 41.9M | 19.3M | 17.0M | 16.6M | 17.1M | 15.1M | 14.8M | 14.8M | 11.0M | 13.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.6M | $4.8M | $6.3M | $2.6M | $730.5K | $1.2M |
| Short-term investments | $4.5M | $4.6M | $4.7M | $4.9M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $8.2M | $9.5M | $11.1M | $7.6M | $868.3K | $1.4M |
| Total liabilities | $40.8K | $114.8K | $702.1K | $83.9K | $298.5K | $106.2K |
| Shareholders' equity | $8.2M | $9.3M | $10.4M | $7.5M | $569.9K | $1.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology